322 results
The primary objective of the study is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately controlled with…
Primary Objective:Pilot study: Selection of the titanium derivatives which are capable of penetrating the skin, and thus can be used in the full study as patch test materials.Full study: To compare the results of three different diagnostic tests…
The purpose of this study is to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe psoriasis may lead to prolonged symptom-free periods by preventing reactivation of old…
The main objective of this study is to investigate the effect of a topically applied emollient enriched with barrier lipids on the barrier properties of skin of AE patients.
The primary objective of this study is to compare the therapeutic effect on atopic dermatitis of a skin barrier repair cream (Dermalex eczema) in contrast to a standard used emollient (unguentum leniens FNA) and a dermatocorticoid (hydrocortisone)…
To compare the efficacy of alitretinoin and azathioprine in the treatment of severe chronic non-hyperkeratotic hand eczema.
Primary objectiveTo compare the efficacy of subpurpuric pulsed dye laser treatment with different intervals between treatment sessions.Secondary objectiveTo evaluate the safety and the long-term effects of subpurpuric pulsed dye laser treatment.
To study wether a biodressing impregnated with polyhexamethylene biguanide in the treatment of spoke injuries in children could give a reduction in pain during the treatment compared to the standard treatment with wound dressing impregnated with
Primary: To demonstrate the superiority of secukinumab 150 mg and/or 300 mg to placebo in subjects with moderate to severe palmoplantar psoriasis as assessed by the palmoplantar Investigator*s Global Assessment (ppIGA) at Week 16.Secondary: Efficacy…
The primary objective is to compare the efficacy and safety of SD-101-6.0vs. SD- 101-0.0 (placebo) in patients with Simplex, RecessiveDystrophic, or Junctional non Herlitz Epidermolysis Bullosa.The primary endpoint is the complete closure of the…
The purpose of this study is to investigate the effectiveness and safety of riociguat (BAY 63-2521) in patients with diffuse cutaneous systemic sclerosis.
In this study, the following questions will be answered:1. Does larval therapy accelerate wound healing?2. Do single larval secretions accelerate wound healing?3. Is the bacterial load in the wound reduced during larval therapy or is the microbiome…
Our aim is to determine whether Wireless Micro Current Stimulation accelerates wound healing in hard-to-heal chronic wounds as compared to standard wound care treatment by conducting a double-blind, placebo controlled trial.
To determine if 6 days of antibiotics has equal efficacy compared to 12 days for patients hospitalized with cellulitis.
Scar volume and POSAS score will be measured in the Verapamil group, these will be compared to the scar volume and POSAS score in the Kenacort+Verapamil group and the Kenacort group. In addition, complications/ adverse effects will be reported.
To evaluate the additional effect of coal tar treatment to a corticosteroid regimen in adults (aged >16 years of age) with moderate to severe atopic dermatitis, based on the percentage change in Eczema Area and Severity Index (EASI) at week 2…
To investigate the acceptability and feasibility of exercise therapy in an aquatic environment by patients after burn injury.
Objective: We want to extend our understanding of the disease aetiology by performing a small pilot study that incorporates other immunologic sites involved in the disease (the skin and the microbiome) while additionally strengthening our disease…
Primary objective: To prospectively evaluate the lesion (AN-)count, i.e. abscesses, inflammatory nodules, and draining sinuses, in the axilla treated with MWA compared to the untreated contralateral axilla after six months.Secondary objectives: - To…
Primary: To demonstrate that the efficacy of secukinumab 150 mg s.c. or 300 mg s.c., at Week 24 is superior to placebo based on proportion of subjects achieving ACR20 response in subjects with active PsA.Secondary:- PASI75 week 24- PASI90 week 24-…